<DOC>
	<DOC>NCT01452009</DOC>
	<brief_summary>A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%</brief_summary>
	<brief_title>Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. Patients 18 years of age or older 2. Either gender 3. Any race/ethnicity 4. Diagnosed with openangle glaucoma (including patients with pseudoexfoliation and pigment dispersion) or ocular hypertension 1. Patients with any form of glaucoma other than openangle glaucoma. 2. Patients with a central cornea thickness greater than 620 μm 3. Patients with Shaffer angle Grade &lt; 2 4. Patients with a cup/disc ratio greater than 0.80 5. Patients with severe central visual field loss 6. BestCorrected Visual Acuity score worse than 55 ETDRS letters (20/80 Snellen equivalent) 7. Chronic, recurrent or severe inflammatory eye disease 8. Clinically significant or progressive retinal disease 9. Other ocular pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>open angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>